GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Insider Ownership

Aroa Biosurgery (ASX:ARX) Insider Ownership : 0.00 % (As of Jun. 09, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aroa Biosurgery's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aroa Biosurgery's Institutional Ownership is 11.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aroa Biosurgery's Float Percentage Of Total Shares Outstanding is 0.00%.


Aroa Biosurgery Insider Ownership Historical Data

The historical data trend for Aroa Biosurgery's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Insider Ownership Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Insider Ownership
- - - - -

Aroa Biosurgery Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Insider Ownership Get a 7-Day Free Trial - - - - -

Aroa Biosurgery Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Aroa Biosurgery (ASX:ARX) Business Description

Traded in Other Exchanges
N/A
Address
64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines